Visudyne Articles
Valeant Pharma acquires Visudyne from QLT
25 September 2012
QLT sees 3rd-qtr profit, but job cuts planned
5 November 2007
QLT's 1st-qtr 2007 EPS falls 54% on Visudyne
7 May 2007
CHMP recommends revoking approval of Visudyne for CNV
30 April 2007
Novartis sees strong performance with record results in 2005
30 January 2006
Sales of Visudyne rise 18% in 3rd qtr
18 July 2005
UK industry figure slams lack of drug access
8 November 2004
QLT posts 27% rise in income for 3rd qtr
1 November 2004
QLT's revenues up 22% in 2nd-qtr 2004
2 August 2004
2nd- qtr Visudyne sales up 22.6% to $109.3M
26 July 2004
Visudyne cleared in Japan for AMD
27 October 2003
New NICE guidances for England and Wales
6 October 2003
QLT's 1st-qtr Visudyne sales up 20%
21 April 2003
US consumers sue over Prilosec and Visudyne
19 August 2002
QLT posts 27% 2nd-qtr Visudyne sales gain
5 August 2002
Glivec gets go-ahead for GIST in Europe
10 June 2002
Alcon AMD drug may rival Visudyne
13 May 2002
Novartis Ophthalmics files Visudyne NDA in Japan
29 April 2002
QLT therapy sales increase significantly
29 April 2002
Allergan in $41M eye deal with EntreMed
28 January 2002
Update: Novartis files new indication for Gleevec in USA
24 October 2001
Novartis/QLT file for further Visudyne use
7 September 2001
Visudyne approved for new indications
23 August 2001
Novartis's Visudyne use extended in EU
26 March 2001
QLT boosted by new Visudyne data
9 February 2001
Expanded use backing on Visudyne from FDA
5 February 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Visudyne nears new indication in EU
15 December 2000
CIBA and QLT file for new Visudyne label
5 October 2000
CIBA's Visudyne makes market entrance in UK
28 September 2000
CIBA and QLT gain priority review for new Visudyne use
31 August 2000
Europe backs CIBA's Visudyne for AMD
31 July 2000
QLT files counterclaim over Visudyne
6 July 2000
In wake of US decision, CPMP backs Visudyne
17 April 2000
In wake of US decision, CPMP backs Visudyne
14 April 2000
CIBA/QLT's Visudyne gets FDA backing
13 April 2000
Long-term efficacy with CIBA's Visudyne
29 March 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
FDA approvable letter for CIBA's Visudyne
16 February 2000
CIBA Vision's Visudyne cleared in first market, Switzerland
16 December 1999
QLT PhotoTherapeutics' Visudyne likely to be approved by FDA
18 November 1999
Novartis upbeat at biannual R&D update
23 September 1999
QLT and CIBA's Visudyne gains priority review
26 August 1999
QLT and CIBA file for Swiss Visudyne approval
20 August 1999
QLT soars to record high on Visudyne filing
18 August 1999
QLT and CIBA file Visudyne in Europe
11 August 1999
QLT's shares boosted on Photofrin approval
21 July 1999
BI and QLT terminate Photofrin contract
1 July 1999
Showing 1-69 of 69 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
